Abstract：Objective To investigate the clinical effect of repetitive transcranial magnetic stimulation (rTMS) in patients with epilepsy after stroke. Methods A total of 104 patients with post-stroke epilepsy treated in the Second Medical Center of PLA General Hospital from January 2021 to March 2023 were divided into observation group (n=52) and control group (n=52) using envelope method. The control group received routine treatment, while the observation group received rTMS treatment on the basis of the control group. The therapeutic effect and seizure status of the two groups were observed. Results The total effective rate of the observation group was 96.15%, which was better than that of the control group (P<0.05). After treatment, the frequency and duration of attacks in the observation group were (1.01±0.27) times/month and (2.20±0.74) min/time, respectively, which were lower than those in the control group (P<0.05). The Mini-mental State Examination (MMSE) score of the observation group after treatment was (25.54±2.01), which was higher than that of the control group (P<0.05), while the National Institutes of Health Stroke Scale (NIHSS) score was (6.14±1.82), which was lower than that of the control group (P<0.05). The scores of social function, physical function, psychological function, and material function on the GQOL-74 comprehensive assessment questionnaire for quality of life after treatment in the observation group were (86.65±9.55) points, (72.82±8.02) points, (80.03±8.33) points, and (83.34±7.94) points, respectively, which was higher than those in the control group (P<0.05). After treatment, serum homocysteine (Hcy), S100 calcium binding protein B (S100B), and neuron specific enolase (NSE) in the observation group were (7.22±1.93) μmol/L, (0.30±0.18) μg/L, and (5.65±1.12) μg/L, respectively, which were lower than those in the control group (P<0.05). Conclusions rTMS intervention has a good effect on patients with epilepsy after stroke, which is beneficial to the control of epilepsy and can improve the neurological and cognitive functions of the patients.
李雪峰, 王英昭, 孙博, 崔艳文. 脑卒中后癫痫患者采用重复经颅刺激干预的临床效果[J]. 武警医学, 2024, 35(10): 880-884.
LI Xuefeng, WANG Yingzhao, SUN Bo, CUI Yanwen. Clinical effect of repetitive transcranial magnetic stimulation in patients with epilepsy after stroke. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(10): 880-884.
Feske S K. Ischemic stroke[J]. Am J Med, 2021,134(12):1457-1464.
[2]
Cai M, Zhang J L, Wang X J, et al. Clinical application of repetitive transcranial magnetic stimulation in improving functional impairments post-stroke: review of the current evidence and potential challenges[J]. Neurol Sci, 2024,45(4):1419-1428.
[3]
Galovic M, Ferreira-Atuesta C, Abraira L, et al. Seizures and epilepsy after stroke: epidemiology, biomarkers and management[J]. Drugs aging, 2021,38(4):285-299.
[4]
Lefaucheur J, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018)[J]. Clin Neurophysiol, 2020,131(2):474-528.
[5]
Luo J, Feng Y, Hong Z, et al. High-frequency repetitive transcranial magnetic stimulation promotes neural stem cell proliferation after ischemic stroke[J]. Neural Regen Res, 2024,19(8):1772-1780.
Jia X, Wang Z, Huang F, et al. A comparison of the Mini-Mental State Examination (MMSE) with the Montreal Cognitive Assessment (MoCA) for mild cognitive impairment screening in Chinese middle-aged and older population: a cross-sectional study[J]. BMC Psychiatry, 2021,21(1):485.
[8]
Zheng Y, Lei F, Liu B. Cancer diagnosis disclosure and quality of life in elderly cancer patients[J]. Healthcare, 2019,7(4):163.
[9]
Runde D. Calculated decisions: NIH stroke scale/score (NIHSS)[J]. Emerg Med Pract, 2020,22(7):CD6-CD7.
[10]
Phan J, Ramos M, Soares T, et al. Poststroke seizure and epilepsy: a review of incidence, risk factors, diagnosis, pathophysiology, and pharmacological therapies[J]. Oxid Med Cell Longev, 2022,2022:1-15.
[11]
Altman K, Shavit-Stein E, Maggio N. Post stroke seizures and epilepsy: from proteases to maladaptive plasticity[J]. Front Cell Neurosci, 2019,13:397.
Walton D, Spencer D C, Nevitt S J, et al. Transcranial magnetic stimulation for the treatment of epilepsy[J]. Cochrane DB Syst Rev, 2021,2021(4):CD11025.
[14]
Zuo C, Cao H, Feng F, et al. Repetitive transcranial magnetic stimulation exerts anti-inflammatory effects via modulating glial activation in mice with chronic unpredictable mild stress-induced depression[J]. Int Immunopharmacol, 2022,109:108788.
[15]
Xing Y, Zhang Y, Li C, et al. Repetitive transcranial magnetic stimulation of the brain after ischemic stroke: Mechanisms from Animal Models[J]. Cell Mol Neurobiol, 2023,43(4):1487-1497.
[16]
Pan F, Mou T, Shao J, et al. Effects of neuronavigation-guided rTMS on serum BDNF, TrkB and VGF levels in depressive patients with suicidal ideation[J]. J Affect Disord, 2023,323:617-623.
[17]
Gurdiel-Álvarez F, Navarro-López V, Varela-Rodríguez S, et al. Transcranial magnetic stimulation therapy for central post-stroke pain: systematic review and meta-analysis[J]. Front Neurosci,2024,18:1345128.
Sohn M N, Brown J C, Sharma P, et al. Pharmacological adjuncts and transcranial magnetic stimulation-induced synaptic plasticity: a systematic review[J]. J Psychiatry Neurosci,2024,49(1):E59-E76.
[20]
Zhao M, Liu A, Wu J, et al. Il1r2 and Tnfrsf12a in transcranial magnetic stimulation effect of ischemic stroke via bioinformatics analysis[J]. Medicine (Baltimore),2024,103(4):e36109.
[21]
Stirton H, Meek B P, Edel A L, et al. Oxolipidomics profile in major depressive disorder: comparing remitters and non-remitters to repetitive transcranial magnetic stimulation treatment[J]. PLoS One, 2021,16(2):e246592.
[22]
Liu L, Ding M, Wu J, et al. High-frequency repetitive transcranial magnetic stimulation promotes ipsilesional functional hyperemia and motor recovery in mice with ischemic stroke[J]. Cereb Cortex, 2024,34(3):bhae074.
2024, Vol. 35 
